. 2019 Sep 18;14(9):e0221709. doi: 10.1371/journal.pone.0221709

Table 5. Sensitivity analyses: Long term assessment (Toxoscreen project).

Sensitivity analyses	Strictly Toxoplasma- Related Events	Global Events
*Epidemiological context*
Northern European country or United States (prevalence: 10%, incidence: 0.05%)
Differential cost	-113
Event differential per 1000 women screened^a	0.01	3.46
Cost per additional outcome avoided	9,107,766	32,724
Southern European countries (prevalence: 50%, incidence: 1%)
Differential cost	-55
Event differential per 1000 women screened^a	0.14	3.67
Cost per additional outcome avoided	406,308	15,276
*Spiramycin Efficacy*
25% reduction of the materno-fetal transmission
Differential cost	-76
Event differential per 1000 women screened^a	0.02	3.49
Cost per additional outcome avoided	3,311,013	21,625
75% reduction of the materno-fetal transmission
Differential cost	-75
Event differential per 1000 women screened^a	0.1	3.51
Cost per additional outcome avoided	754,215	21,302
*Antenatal screening participation rate*
50% participation rate
Differential cost	-47
Event differential per 1000 women screened^a	0.03	2.19
Cost per additional outcome avoided	1,795,488	21,472
100% participation rate
Differential cost	-94
Event differential per 1000 women screened^a	0.05	4.38
Cost per additional outcome avoided	1,788,429	21,473

^a: Cost and event differential are calculated following the same formula: results with the neonatal screening minus results with the prenatal screening